Z Tadrist

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

Véronique Gelsi‐Boyer, Virginie Trouplin, Julien Roquain et al. · British Journal of Haematology · 2010 · 217 citations · Full text

Medicine, Hematology, Molecular Genetics +17

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

Julien Rocquain, Nadine Carbuccia, Virginie Trouplin et al. · BMC Cancer · 2010 · 171 citations · Full text

Medicine, Genetics, Hematology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.

J.M. Tourani, C. Pfister, J.F. Berdah et al. · Journal of Clinical Oncology · 1998 · 78 citations

Medicine, Oncology, Pharmacotherapy +17

[Interferon alpha and pamidronate: a useful combination in the treatment of osteoporosis and systemic mastocytosis].

Brunel, Z Tadrist, S. Caillères et al. · PubMed · 1998 · 20 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +8